Cover Image
市場調查報告書

全球糖尿病腎病變市場

Global Diabetic Nephropathy Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 298333
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
全球糖尿病腎病變市場 Global Diabetic Nephropathy Market 2014-2018
出版日期: 2014年03月14日 內容資訊: 英文 64 Pages
簡介

糖尿病腎病變(DN)的全球市場,預計從2013年到2018年,以5.19%的年複合成長率擴大。

本報告提供全球糖尿病腎病變市場現狀與未來預測,再加上主要企業分析等等,為您概述為以下內容。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品
  • 產品簡介

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 美國的DN市場
  • 歐洲的DN市場
  • 波特的五力分析

第7章 開發平台概要

第8章 罹患率和得病率

第9章 地理區分

  • 南北美洲的DN市場
  • EMEA(歐洲中東非洲)地區的DN市場
  • 亞太地區的DN市場

第10章 購買標準

第11章 市場成長因素

第12章 成長因素與其影響

第13章 市場課題

第14章 成長因素與課題的影響

第15章 市場趨勢

第16章 趨勢與其影響

第17章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
  • 其他卓越供應商

第18章 主要供應商分析

  • Merck & Co. Inc.
  • 三菱田邊製藥
  • Novartis AG
  • Sanofi S.A.

第19章 相關報告

目錄
Product Code: IRTNTR3393

About Diabetic Nephropathy

Diabetic nephropathy is a disease of the kidney glomerulus, which is caused by high blood sugar. When diabetes damages kidneys, which contain millions of tiny blood vessel clusters (glomeruli) that filter waste from the blood, this results in diabetic nephropathy, which is also known as diabetic kidney disease. Severe damage can lead to kidney failure or irreversible ESRD, requiring dialysis or a kidney transplant. Hypertension, or high blood pressure, is a complication of diabetes that is believed to contribute most directly to diabetic nephropathy. Treatment to limit progression of diabetic nephropathy involves glycemic control and blood pressure control.

TechNavio's analysts forecast the Global Diabetic Nephropathy market will grow at a CAGR of 5.19 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Diabetic Nephropathy market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various diabetic nephropathy drugs available in the market.

TechNavio's report, the Global Diabetic Nephropathy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Diabetic Nephropathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Novartis AG
  • Sanofi S.A.

Other Prominent Vendors

  • AbbVie Inc.
  • Ampio Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • ChemoCentryx Inc.
  • Eli Lilly and Co.
  • GenKyoTex S.A.
  • Glycadia Pharmaceuticals Inc.
  • IMMD Inc.
  • Mesoblast Ltd.
  • NephroGenex Inc.
  • Novo Nordisk A/S
  • NOXXON Pharma AG
  • OncoImmune Inc.
  • Pfizer Inc.
  • PhytoHealth Corp.
  • Questcor Pharmaceuticals Inc.
  • Reata Pharmaceuticals Inc.

Key Market Driver

  • Increase in Prevalence of Diabetes.

For a full, detailed list, view our report.

Key Market Challenge

  • Increasing Number of Patent Expirations.

For a full, detailed list, view our report.

Key Market Trend

  • Increase in Awareness of Diabetic Nephropathy Drugs.

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. DN Market in the US
    • 06.3.1. Market Size and Forecast
  • 06.4. DN Market in Europe
    • 06.4.1. Market Size and Forecast
  • 06.5. Five Forces Analysis

07. Pipeline Snapshot

08. Rate of Incidence and Prevalence

09. Geographical Segmentation

  • 09.1. DN Market in the Americas
    • 09.1.1. Market Size and Forecast
  • 09.2. DN Market in the EMEA Region
    • 09.2.1. Market Size and Forecast
  • 09.3. DN Market in the APAC Region
    • 09.3.1. Market Size and Forecast

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Market Share Analysis 2013
  • 17.3. Other Prominent Vendors

18. Key Vendor Analysis

  • 18.1. Merck & Co. Inc.
    • 18.1.1. Business Overview
    • 18.1.2. Business Segmentation
    • 18.1.3. Key Information
    • 18.1.4. SWOT Analysis
  • 18.2. Mitsubishi Tanabe Pharma Corp.
    • 18.2.1. Business Overview
    • 18.2.2. Key Information
    • 18.2.3. SWOT Analysis
  • 18.3. Novartis AG
    • 18.3.1. Business Overview
    • 18.3.2. Business Segmentation
    • 18.3.3. Key Information
    • 18.3.4. SWOT Analysis
  • 18.4. Sanofi S.A.
    • 18.4.1. Business Overview
    • 18.4.2. Business Segmentation
    • 18.4.3. Key Information
    • 18.4.4. SWOT Analysis

19. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global DN Market 2013-2018 (US$ billion)
  • Exhibit 3: DN Market in the US 2013-2018 (US$ billion)
  • Exhibit 4: DN Market in Europe 2013-2018 (US$ billion)
  • Exhibit 5: Global DN Market by Geographical Segmentation 2013
  • Exhibit 6: DN Market in the Americas 2013-2018 (US$ billion)
  • Exhibit 7: DN Market in the EMEA Region 2013-2018 (US$ billion)
  • Exhibit 8: DN Market in the APAC Region (US$ billion)
  • Exhibit 9: Global DN Market by Geographical Segmentation
  • Exhibit 10: Business Segmentation of Merck & Co. Inc.
  • Exhibit 11: Business Segmentation of Novartis AG
  • Exhibit 12: Business Segmentation of Sanofi S.A.
Back to Top